Yoshitaka Nishikawa, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Japan | 52 | 2024 | 1415 | 2.650 |
Why?
|
| Disasters | 14 | 2023 | 520 | 1.930 |
Why?
|
| Helicobacter pylori | 5 | 2024 | 380 | 1.570 |
Why?
|
| Hyperammonemia | 3 | 2023 | 80 | 1.470 |
Why?
|
| Helicobacter Infections | 4 | 2024 | 390 | 1.080 |
Why?
|
| Earthquakes | 7 | 2023 | 193 | 0.950 |
Why?
|
| Fluorouracil | 5 | 2023 | 1648 | 0.810 |
Why?
|
| Iodine | 2 | 2019 | 288 | 0.650 |
Why?
|
| Adenocarcinoma | 3 | 2024 | 6364 | 0.620 |
Why?
|
| Nuclear Power Plants | 7 | 2023 | 13 | 0.620 |
Why?
|
| Fluoroacetates | 2 | 2020 | 13 | 0.610 |
Why?
|
| Facility Design and Construction | 1 | 2018 | 88 | 0.590 |
Why?
|
| Intestine, Small | 2 | 2024 | 1214 | 0.580 |
Why?
|
| Whole-Body Counting | 4 | 2019 | 36 | 0.580 |
Why?
|
| Dilatation | 2 | 2017 | 310 | 0.580 |
Why?
|
| Transportation of Patients | 1 | 2019 | 178 | 0.580 |
Why?
|
| beta-Alanine | 2 | 2020 | 83 | 0.570 |
Why?
|
| Intestinal Neoplasms | 1 | 2020 | 313 | 0.570 |
Why?
|
| Acupuncture Therapy | 1 | 2021 | 466 | 0.550 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2020 | 647 | 0.550 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2024 | 11868 | 0.540 |
Why?
|
| Glucuronosyltransferase | 1 | 2016 | 136 | 0.510 |
Why?
|
| Colonoscopy | 6 | 2024 | 1406 | 0.510 |
Why?
|
| Radiation Monitoring | 4 | 2017 | 106 | 0.510 |
Why?
|
| Colorectal Neoplasms | 8 | 2024 | 6942 | 0.500 |
Why?
|
| Long-Term Care | 2 | 2021 | 629 | 0.490 |
Why?
|
| Nursing Homes | 3 | 2022 | 1084 | 0.480 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2019 | 540 | 0.480 |
Why?
|
| Renal Dialysis | 5 | 2023 | 1799 | 0.480 |
Why?
|
| Cathartics | 1 | 2016 | 129 | 0.480 |
Why?
|
| Stomach Diseases | 1 | 2016 | 134 | 0.470 |
Why?
|
| Esophageal Stenosis | 1 | 2016 | 196 | 0.460 |
Why?
|
| Anti-Infective Agents | 1 | 2021 | 986 | 0.440 |
Why?
|
| Endoscopy | 2 | 2022 | 1841 | 0.440 |
Why?
|
| Stomach | 3 | 2019 | 699 | 0.440 |
Why?
|
| Home Care Services | 4 | 2021 | 660 | 0.430 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2015 | 394 | 0.410 |
Why?
|
| Lymphatic Metastasis | 2 | 2020 | 2887 | 0.410 |
Why?
|
| Protoporphyria, Erythropoietic | 1 | 2013 | 54 | 0.400 |
Why?
|
| Decontamination | 3 | 2021 | 73 | 0.380 |
Why?
|
| Colonic Polyps | 3 | 2021 | 556 | 0.380 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2016 | 451 | 0.370 |
Why?
|
| beta Carotene | 1 | 2013 | 522 | 0.370 |
Why?
|
| Azacitidine | 1 | 2013 | 334 | 0.370 |
Why?
|
| Stomach Neoplasms | 5 | 2024 | 1471 | 0.360 |
Why?
|
| Esophagus | 2 | 2017 | 1037 | 0.360 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2013 | 238 | 0.360 |
Why?
|
| Catheterization | 1 | 2016 | 1425 | 0.350 |
Why?
|
| Polyethylene Glycols | 1 | 2016 | 1188 | 0.340 |
Why?
|
| Mass Screening | 2 | 2024 | 5446 | 0.330 |
Why?
|
| Humans | 104 | 2024 | 765968 | 0.320 |
Why?
|
| Patient Compliance | 1 | 2019 | 2692 | 0.310 |
Why?
|
| Occupational Exposure | 3 | 2024 | 1805 | 0.290 |
Why?
|
| Thyroid Neoplasms | 2 | 2019 | 2371 | 0.290 |
Why?
|
| Immunoglobulin M | 3 | 2022 | 1528 | 0.290 |
Why?
|
| Immunoglobulin G | 5 | 2022 | 4528 | 0.290 |
Why?
|
| Cesium Radioisotopes | 2 | 2017 | 38 | 0.280 |
Why?
|
| Calcinosis | 1 | 2016 | 1479 | 0.280 |
Why?
|
| Preoperative Care | 1 | 2016 | 2267 | 0.270 |
Why?
|
| Antibodies, Viral | 6 | 2023 | 3211 | 0.260 |
Why?
|
| Polymorphism, Genetic | 1 | 2016 | 4247 | 0.260 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2014 | 2024 | 0.250 |
Why?
|
| Proteinuria | 3 | 2024 | 607 | 0.240 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 2699 | 0.240 |
Why?
|
| Caregivers | 3 | 2023 | 2307 | 0.230 |
Why?
|
| Emergencies | 2 | 2021 | 1223 | 0.230 |
Why?
|
| Antineoplastic Agents | 3 | 2023 | 13648 | 0.230 |
Why?
|
| Silicosis | 1 | 2024 | 47 | 0.230 |
Why?
|
| Endoscopy, Gastrointestinal | 2 | 2022 | 888 | 0.220 |
Why?
|
| Demography | 3 | 2023 | 1641 | 0.220 |
Why?
|
| Male | 51 | 2024 | 363698 | 0.220 |
Why?
|
| Tegafur | 1 | 2023 | 39 | 0.210 |
Why?
|
| Landslides | 1 | 2022 | 2 | 0.210 |
Why?
|
| Aged | 30 | 2024 | 171117 | 0.210 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2013 | 1404 | 0.210 |
Why?
|
| Community Pharmacy Services | 1 | 2023 | 51 | 0.200 |
Why?
|
| Antimetabolites | 1 | 2023 | 127 | 0.200 |
Why?
|
| Antipyretics | 1 | 2022 | 22 | 0.200 |
Why?
|
| Neoplasms | 5 | 2024 | 22340 | 0.190 |
Why?
|
| Retrospective Studies | 21 | 2024 | 81514 | 0.190 |
Why?
|
| Dust | 1 | 2024 | 489 | 0.190 |
Why?
|
| Activities of Daily Living | 4 | 2023 | 2415 | 0.180 |
Why?
|
| Breast Neoplasms | 3 | 2023 | 21056 | 0.180 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 4044 | 0.180 |
Why?
|
| Chickenpox | 1 | 2021 | 95 | 0.180 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2024 | 279 | 0.180 |
Why?
|
| Ambulances | 1 | 2021 | 94 | 0.180 |
Why?
|
| Blood Glucose | 1 | 2015 | 6424 | 0.170 |
Why?
|
| Hemopneumothorax | 1 | 2020 | 4 | 0.170 |
Why?
|
| Ammonia | 2 | 2020 | 244 | 0.170 |
Why?
|
| Foot-and-Mouth Disease | 1 | 2019 | 7 | 0.170 |
Why?
|
| Middle Aged | 32 | 2024 | 223009 | 0.170 |
Why?
|
| Models, Biological | 1 | 2016 | 9443 | 0.160 |
Why?
|
| Rural Health | 1 | 2021 | 301 | 0.160 |
Why?
|
| Editorial Policies | 1 | 2024 | 458 | 0.160 |
Why?
|
| Population Dynamics | 2 | 2019 | 314 | 0.160 |
Why?
|
| Positron-Emission Tomography | 2 | 2019 | 6547 | 0.160 |
Why?
|
| Schools | 2 | 2018 | 1492 | 0.160 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2019 | 86 | 0.160 |
Why?
|
| Female | 41 | 2024 | 396112 | 0.160 |
Why?
|
| Conflict of Interest | 1 | 2024 | 556 | 0.160 |
Why?
|
| Health Care Costs | 2 | 2023 | 3242 | 0.160 |
Why?
|
| Foot Ulcer | 1 | 2019 | 63 | 0.160 |
Why?
|
| Herpes Zoster | 1 | 2021 | 252 | 0.160 |
Why?
|
| Personnel, Hospital | 1 | 2021 | 286 | 0.160 |
Why?
|
| Health Facility Closure | 1 | 2019 | 24 | 0.160 |
Why?
|
| Vascular Fistula | 1 | 2019 | 50 | 0.160 |
Why?
|
| Pesticides | 1 | 2021 | 296 | 0.150 |
Why?
|
| Urinary Incontinence | 1 | 2023 | 491 | 0.150 |
Why?
|
| Cyclonic Storms | 1 | 2020 | 121 | 0.150 |
Why?
|
| Radiation | 1 | 2018 | 48 | 0.150 |
Why?
|
| Rib Fractures | 1 | 2020 | 124 | 0.150 |
Why?
|
| Accidents, Occupational | 1 | 2020 | 251 | 0.150 |
Why?
|
| Intestinal Fistula | 1 | 2019 | 146 | 0.150 |
Why?
|
| Aged, 80 and over | 16 | 2023 | 59489 | 0.150 |
Why?
|
| Kidney Failure, Chronic | 2 | 2023 | 2495 | 0.140 |
Why?
|
| Terminal Care | 2 | 2021 | 1774 | 0.140 |
Why?
|
| Radioactive Pollutants | 1 | 2017 | 13 | 0.140 |
Why?
|
| Evaluation Studies as Topic | 1 | 2020 | 1600 | 0.140 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2022 | 424 | 0.140 |
Why?
|
| Lymph Node Excision | 1 | 2023 | 1259 | 0.140 |
Why?
|
| Albumins | 1 | 2020 | 577 | 0.140 |
Why?
|
| Gastric Mucosa | 2 | 2020 | 602 | 0.140 |
Why?
|
| Antigens, Viral | 1 | 2021 | 995 | 0.140 |
Why?
|
| Cecal Neoplasms | 1 | 2016 | 27 | 0.130 |
Why?
|
| Insurance Claim Review | 1 | 2021 | 746 | 0.130 |
Why?
|
| Paraneoplastic Syndromes, Nervous System | 1 | 2016 | 24 | 0.130 |
Why?
|
| Limbic Encephalitis | 1 | 2016 | 36 | 0.130 |
Why?
|
| Esophageal Achalasia | 1 | 2017 | 99 | 0.130 |
Why?
|
| Vaccination | 6 | 2024 | 3426 | 0.130 |
Why?
|
| Deficiency Diseases | 1 | 2016 | 75 | 0.130 |
Why?
|
| Arteriovenous Malformations | 1 | 2019 | 397 | 0.130 |
Why?
|
| Robotics | 1 | 2023 | 809 | 0.130 |
Why?
|
| Gastritis | 1 | 2017 | 200 | 0.120 |
Why?
|
| Rescue Work | 1 | 2015 | 58 | 0.120 |
Why?
|
| Education | 1 | 2018 | 533 | 0.120 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2015 | 92 | 0.120 |
Why?
|
| Bullying | 1 | 2018 | 234 | 0.120 |
Why?
|
| Bayes Theorem | 2 | 2023 | 2354 | 0.120 |
Why?
|
| Mechanical Phenomena | 1 | 2016 | 141 | 0.120 |
Why?
|
| Tsunamis | 1 | 2015 | 61 | 0.120 |
Why?
|
| Rupture | 1 | 2016 | 443 | 0.110 |
Why?
|
| Epithelium | 1 | 2019 | 1599 | 0.110 |
Why?
|
| Vaccines | 1 | 2022 | 841 | 0.110 |
Why?
|
| Hospitals | 3 | 2023 | 3888 | 0.110 |
Why?
|
| Cooperative Behavior | 1 | 2021 | 1509 | 0.110 |
Why?
|
| Early Detection of Cancer | 3 | 2024 | 3236 | 0.110 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 8529 | 0.110 |
Why?
|
| Epidemics | 1 | 2019 | 514 | 0.110 |
Why?
|
| Doxorubicin | 1 | 2020 | 2230 | 0.110 |
Why?
|
| Health Personnel | 3 | 2022 | 3390 | 0.110 |
Why?
|
| Hypersensitivity | 1 | 2022 | 1168 | 0.110 |
Why?
|
| Periodicals as Topic | 1 | 2024 | 1462 | 0.110 |
Why?
|
| Patient Transfer | 1 | 2020 | 790 | 0.110 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2014 | 348 | 0.100 |
Why?
|
| Cytomegalovirus | 1 | 2017 | 751 | 0.100 |
Why?
|
| Adult | 21 | 2024 | 223044 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2019 | 9373 | 0.100 |
Why?
|
| Paclitaxel | 1 | 2020 | 1728 | 0.100 |
Why?
|
| Survival Analysis | 2 | 2024 | 10070 | 0.100 |
Why?
|
| Physicians | 2 | 2022 | 4588 | 0.100 |
Why?
|
| Pressure | 1 | 2016 | 1168 | 0.100 |
Why?
|
| Geography | 3 | 2021 | 652 | 0.100 |
Why?
|
| Patient Participation | 1 | 2021 | 1455 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2019 | 20659 | 0.100 |
Why?
|
| Lymphoma, Follicular | 1 | 2016 | 459 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 13451 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2022 | 2056 | 0.100 |
Why?
|
| Precancerous Conditions | 1 | 2019 | 976 | 0.100 |
Why?
|
| Infant | 8 | 2021 | 36386 | 0.100 |
Why?
|
| Statistics as Topic | 1 | 2018 | 2352 | 0.090 |
Why?
|
| Benzoates | 1 | 2013 | 213 | 0.090 |
Why?
|
| Esophageal Neoplasms | 2 | 2019 | 1661 | 0.090 |
Why?
|
| Floods | 2 | 2022 | 43 | 0.090 |
Why?
|
| Child, Preschool | 8 | 2021 | 42500 | 0.090 |
Why?
|
| Prognosis | 4 | 2024 | 29922 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2022 | 3513 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 691 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 12240 | 0.090 |
Why?
|
| Cytomegalovirus Infections | 1 | 2017 | 836 | 0.090 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2015 | 318 | 0.090 |
Why?
|
| Social Class | 1 | 2019 | 2007 | 0.090 |
Why?
|
| Vascular Surgical Procedures | 1 | 2019 | 1485 | 0.090 |
Why?
|
| Nephrotic Syndrome | 1 | 2014 | 380 | 0.090 |
Why?
|
| Platelet Transfusion | 1 | 2013 | 296 | 0.080 |
Why?
|
| Diabetic Nephropathies | 1 | 2017 | 969 | 0.080 |
Why?
|
| Critical Illness | 1 | 2022 | 2744 | 0.080 |
Why?
|
| Adolescent | 12 | 2024 | 88835 | 0.080 |
Why?
|
| Disaster Planning | 1 | 2015 | 559 | 0.080 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2024 | 2310 | 0.080 |
Why?
|
| Child | 11 | 2023 | 80564 | 0.080 |
Why?
|
| Emergency Medical Services | 1 | 2021 | 1938 | 0.080 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2019 | 1211 | 0.080 |
Why?
|
| Radius | 2 | 2023 | 440 | 0.080 |
Why?
|
| Colitis | 1 | 2017 | 1239 | 0.080 |
Why?
|
| Carcinoma | 1 | 2020 | 2312 | 0.080 |
Why?
|
| Models, Theoretical | 2 | 2019 | 3564 | 0.080 |
Why?
|
| Prospective Studies | 5 | 2022 | 54802 | 0.080 |
Why?
|
| Parents | 1 | 2023 | 3592 | 0.080 |
Why?
|
| Immunity, Humoral | 2 | 2023 | 605 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2021 | 9649 | 0.080 |
Why?
|
| Antibodies, Neutralizing | 3 | 2022 | 2010 | 0.070 |
Why?
|
| Time Factors | 5 | 2021 | 40065 | 0.070 |
Why?
|
| Equipment Design | 1 | 2016 | 3481 | 0.070 |
Why?
|
| Triazoles | 1 | 2013 | 897 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 6069 | 0.070 |
Why?
|
| Cohort Studies | 4 | 2024 | 41649 | 0.070 |
Why?
|
| Disease Progression | 1 | 2024 | 13632 | 0.070 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 2567 | 0.070 |
Why?
|
| Infant, Newborn | 4 | 2021 | 26346 | 0.070 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 11206 | 0.070 |
Why?
|
| Kidney Function Tests | 2 | 2022 | 683 | 0.070 |
Why?
|
| Weight Loss | 1 | 2017 | 2710 | 0.060 |
Why?
|
| Endoscopy, Digestive System | 2 | 2019 | 358 | 0.060 |
Why?
|
| Pandemics | 2 | 2023 | 8703 | 0.060 |
Why?
|
| Young Adult | 7 | 2021 | 59889 | 0.060 |
Why?
|
| Egypt | 1 | 2024 | 100 | 0.060 |
Why?
|
| Risk Factors | 6 | 2024 | 74840 | 0.060 |
Why?
|
| Mongolia | 1 | 2024 | 93 | 0.060 |
Why?
|
| Fatal Outcome | 2 | 2019 | 1831 | 0.060 |
Why?
|
| Cross-Sectional Studies | 5 | 2023 | 26318 | 0.060 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2014 | 1434 | 0.060 |
Why?
|
| Mining | 1 | 2024 | 93 | 0.060 |
Why?
|
| Telemedicine | 1 | 2021 | 3105 | 0.060 |
Why?
|
| Asthma | 1 | 2022 | 6270 | 0.050 |
Why?
|
| Scientific Misconduct | 1 | 2024 | 77 | 0.050 |
Why?
|
| Smoking | 2 | 2019 | 9081 | 0.050 |
Why?
|
| Health Promotion | 1 | 2015 | 2208 | 0.050 |
Why?
|
| Tokyo | 1 | 2023 | 25 | 0.050 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 3413 | 0.050 |
Why?
|
| Klebsiella pneumoniae | 1 | 2024 | 253 | 0.050 |
Why?
|
| Palliative Care | 1 | 2017 | 3645 | 0.050 |
Why?
|
| Genotype | 1 | 2016 | 13024 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2017 | 4544 | 0.050 |
Why?
|
| Information Seeking Behavior | 1 | 2023 | 116 | 0.050 |
Why?
|
| Acute Kidney Injury | 1 | 2014 | 1946 | 0.050 |
Why?
|
| Pneumonia, Bacterial | 1 | 2024 | 318 | 0.050 |
Why?
|
| Treatment Outcome | 4 | 2023 | 65188 | 0.050 |
Why?
|
| Authorship | 1 | 2024 | 288 | 0.050 |
Why?
|
| Hematologic Neoplasms | 1 | 2013 | 1927 | 0.050 |
Why?
|
| Snow | 1 | 2020 | 15 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2013 | 3461 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 9249 | 0.040 |
Why?
|
| Social Participation | 1 | 2023 | 187 | 0.040 |
Why?
|
| Occult Blood | 1 | 2021 | 198 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 7875 | 0.040 |
Why?
|
| Herpesvirus 3, Human | 1 | 2021 | 159 | 0.040 |
Why?
|
| Insulin | 1 | 2015 | 6599 | 0.040 |
Why?
|
| Pharmacists | 1 | 2023 | 260 | 0.040 |
Why?
|
| Hospitals, Community | 1 | 2023 | 363 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2023 | 11083 | 0.040 |
Why?
|
| Agriculture | 1 | 2021 | 186 | 0.040 |
Why?
|
| Foot-and-Mouth Disease Virus | 1 | 2019 | 4 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2021 | 404 | 0.040 |
Why?
|
| Aging | 1 | 2019 | 8731 | 0.040 |
Why?
|
| Basic Reproduction Number | 1 | 2019 | 38 | 0.040 |
Why?
|
| Thoracostomy | 1 | 2020 | 78 | 0.040 |
Why?
|
| Bangladesh | 1 | 2021 | 745 | 0.040 |
Why?
|
| Animal Husbandry | 1 | 2019 | 64 | 0.040 |
Why?
|
| Complementary Therapies | 1 | 2023 | 487 | 0.040 |
Why?
|
| Melanoma | 1 | 2017 | 5719 | 0.040 |
Why?
|
| Videoconferencing | 1 | 2021 | 209 | 0.040 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2022 | 499 | 0.040 |
Why?
|
| Housing | 1 | 2023 | 683 | 0.040 |
Why?
|
| Cities | 1 | 2021 | 543 | 0.040 |
Why?
|
| Serologic Tests | 1 | 2020 | 382 | 0.040 |
Why?
|
| Disclosure | 1 | 2024 | 756 | 0.040 |
Why?
|
| Cellulitis | 1 | 2020 | 206 | 0.040 |
Why?
|
| Communications Media | 1 | 2018 | 42 | 0.040 |
Why?
|
| Radiography, Thoracic | 1 | 2024 | 1315 | 0.040 |
Why?
|
| Sacrum | 1 | 2019 | 270 | 0.040 |
Why?
|
| Uganda | 1 | 2022 | 1353 | 0.040 |
Why?
|
| Decision Making | 2 | 2022 | 3965 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 39193 | 0.040 |
Why?
|
| Video Recording | 1 | 2022 | 969 | 0.040 |
Why?
|
| Licensure, Medical | 1 | 2018 | 72 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2023 | 1555 | 0.030 |
Why?
|
| Mental Health | 2 | 2022 | 3278 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2011 | 3985 | 0.030 |
Why?
|
| Postoperative Hemorrhage | 1 | 2020 | 413 | 0.030 |
Why?
|
| Knowledge | 1 | 2018 | 178 | 0.030 |
Why?
|
| Creatinine | 1 | 2022 | 1915 | 0.030 |
Why?
|
| Esophagitis | 1 | 2017 | 163 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2019 | 993 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2024 | 12509 | 0.030 |
Why?
|
| Receptor, Notch1 | 1 | 2019 | 517 | 0.030 |
Why?
|
| Outpatients | 1 | 2023 | 1595 | 0.030 |
Why?
|
| Gastrointestinal Tract | 1 | 2021 | 834 | 0.030 |
Why?
|
| Esophagoscopy | 1 | 2017 | 398 | 0.030 |
Why?
|
| Cross Infection | 1 | 2024 | 1427 | 0.030 |
Why?
|
| United States | 1 | 2023 | 72903 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2021 | 790 | 0.030 |
Why?
|
| Clone Cells | 1 | 2019 | 1672 | 0.030 |
Why?
|
| Thoracic Neoplasms | 1 | 2017 | 267 | 0.030 |
Why?
|
| Fever | 1 | 2022 | 1603 | 0.030 |
Why?
|
| Prostatectomy | 1 | 2023 | 1782 | 0.030 |
Why?
|
| Heart Failure | 1 | 2019 | 11840 | 0.030 |
Why?
|
| Language | 1 | 2024 | 1550 | 0.030 |
Why?
|
| Incidence | 2 | 2024 | 21480 | 0.030 |
Why?
|
| Cell Count | 1 | 2019 | 1823 | 0.030 |
Why?
|
| Databases, Factual | 2 | 2021 | 8067 | 0.030 |
Why?
|
| Checklist | 1 | 2021 | 848 | 0.030 |
Why?
|
| Duodenum | 1 | 2017 | 495 | 0.030 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 5370 | 0.030 |
Why?
|
| Mutation | 1 | 2019 | 30198 | 0.030 |
Why?
|
| Advance Care Planning | 1 | 2021 | 702 | 0.030 |
Why?
|
| Vulnerable Populations | 1 | 2019 | 718 | 0.030 |
Why?
|
| Cattle | 1 | 2019 | 3801 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 2022 | 1759 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2020 | 4850 | 0.030 |
Why?
|
| Age Factors | 2 | 2020 | 18380 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2023 | 3139 | 0.020 |
Why?
|
| Deglutition Disorders | 1 | 2017 | 639 | 0.020 |
Why?
|
| Inflammation | 1 | 2011 | 10850 | 0.020 |
Why?
|
| Lower Extremity | 1 | 2019 | 1226 | 0.020 |
Why?
|
| Survivors | 1 | 2021 | 2372 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2017 | 2108 | 0.020 |
Why?
|
| Class Ib Phosphatidylinositol 3-Kinase | 1 | 2011 | 42 | 0.020 |
Why?
|
| Emotions | 1 | 2023 | 2763 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2021 | 2590 | 0.020 |
Why?
|
| Histological Techniques | 1 | 2011 | 193 | 0.020 |
Why?
|
| Evolution, Molecular | 1 | 2019 | 1889 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 2045 | 0.020 |
Why?
|
| Disabled Persons | 1 | 2019 | 1208 | 0.020 |
Why?
|
| Logistic Models | 1 | 2024 | 13266 | 0.020 |
Why?
|
| Swine | 1 | 2019 | 5988 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2022 | 3800 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2019 | 2844 | 0.020 |
Why?
|
| Quinoxalines | 1 | 2011 | 296 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2021 | 2521 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2024 | 3458 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2018 | 6322 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2022 | 5343 | 0.020 |
Why?
|
| Obesity | 1 | 2011 | 13076 | 0.020 |
Why?
|
| Communication | 1 | 2022 | 3916 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2017 | 1944 | 0.020 |
Why?
|
| Nutritional Status | 1 | 2016 | 1620 | 0.020 |
Why?
|
| Radiation Injuries | 1 | 2015 | 1181 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 14751 | 0.020 |
Why?
|
| Thiazolidinediones | 1 | 2011 | 459 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 4772 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2019 | 2535 | 0.020 |
Why?
|
| Life Style | 1 | 2019 | 3926 | 0.020 |
Why?
|
| Biopsy | 1 | 2019 | 6763 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 7838 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2019 | 4040 | 0.020 |
Why?
|
| Lung | 1 | 2024 | 10033 | 0.020 |
Why?
|
| Genome, Human | 1 | 2019 | 4448 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2019 | 6255 | 0.020 |
Why?
|
| Risk | 1 | 2017 | 9591 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2020 | 4862 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 12056 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 14652 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 6832 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2021 | 22223 | 0.010 |
Why?
|
| Sex Factors | 1 | 2017 | 10603 | 0.010 |
Why?
|
| Artificial Intelligence | 1 | 2017 | 2659 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2018 | 4533 | 0.010 |
Why?
|
| Survival Rate | 1 | 2015 | 12795 | 0.010 |
Why?
|
| Quality of Life | 1 | 2023 | 13462 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2017 | 8923 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2011 | 5881 | 0.010 |
Why?
|
| Prevalence | 1 | 2016 | 15842 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2021 | 24282 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 2011 | 3312 | 0.010 |
Why?
|
| Algorithms | 1 | 2019 | 14071 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 15880 | 0.010 |
Why?
|
| Macrophages | 1 | 2011 | 5772 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2011 | 14448 | 0.010 |
Why?
|
| Liver | 1 | 2011 | 7562 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 9525 | 0.010 |
Why?
|
| Animals | 2 | 2019 | 168764 | 0.010 |
Why?
|
| Mice | 1 | 2011 | 81819 | 0.000 |
Why?
|